TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23082602

Group type: EXPERIMENTAL
Intervention: Multi-level oral health intervention (home visits by lay health workers, enhancing oral health education and services at health centers, community mobilization)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental group (caregivers receiving the intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (caregivers not receiving the intervention)
Number of subjects: 0
Study: 21146663

Group type: EXPERIMENTAL
Intervention: Lower height-z patients (n=124, 23%)
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Higher BMI-z patients (n=45, 8%)
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Lower BMI-z patients (n=53, 10%)
Number of subjects: 544
Study: 17986898

Group type: EXPERIMENTAL
Intervention: Treadmill running (SHORT: 30 min, 65% VO2max)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Treadmill running (LONG: 60 min, 65% VO2max)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Treadmill running (INTENSE: 6 x 3 min, 90% VO2max)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Treadmill running (any intensity)
Number of subjects: 18
Study: 15855573

Group type: EXPERIMENTAL
Intervention: GlucoWatch G2 Biographer (GW2B) plus standard glucose monitoring
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard glucose monitoring (usual care)
Number of subjects: 200
Study: 11990270

Group type: EXPERIMENTAL
Intervention: meperidine 10 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 40
Study: 10543733

Group type: EXPERIMENTAL
Intervention: 1 mg/kg of body weight daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2 mg/kg daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 4 mg/kg weekly
Number of subjects: 30

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 30
Study: 8559630

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine (fourth dose)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Acellular pertussis vaccine (booster)
Number of subjects: 182
Study: 2378546

Group type: EXPERIMENTAL
Intervention: 5 mg/d of haloperidol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 10 mg/d of haloperidol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 20 mg/d of haloperidol
Number of subjects: 80
Study: 356962

Group type: EXPERIMENTAL
Intervention: Methotrexate alone
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Methotrexate plus Bacillus Calmette‐Guérin
Number of subjects: 38
Study: 31957952

Group type: EXPERIMENTAL
Intervention: Fractional microneedle radiofrequency (FMR)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fractional radiofrequency (FR)
Number of subjects: 10
Study: 31657804

Group type: EXPERIMENTAL
Intervention: 14 improvisational music therapy sessions on a weekly basis (Group 1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 7 improvisational music therapy sessions alternated with 7 listening music therapy sessions on a weekly basis (Group 2)
Number of subjects: 24
Study: 28382893

Group type: EXPERIMENTAL
Intervention: fruit
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: fruit+reward
Number of subjects: 165

Group type: COMPARATOR
Intervention: unhealthy snacks
Number of subjects: 165
Study: 27116860

Group type: EXPERIMENTAL
Intervention: Rubber dam protection
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cotton rolls isolation (Control)
Number of subjects: 36
Study: 24293132

Group type: EXPERIMENTAL
Intervention: OLM/AML 40/10 mg
Number of subjects: 600

Group type: COMPARATOR
Intervention: PER/AML 8/10 mg
Number of subjects: 600
Study: 20585834

Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing algorithm for warfarin therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mean warfarin requirements ≤ 3 mg/day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mean warfarin requirements > 3 mg/day
Number of subjects: 100
Study: 19217632

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 17902000

Group type: EXPERIMENTAL
Intervention: Therapy group (TG) received one-session cognitive behavior therapy (CBT).
Number of subjects: 26

Group type: COMPARATOR
Intervention: Waiting list group (WG) did not receive therapy during the study period.
Number of subjects: 26
Study: 15334793

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 300

Group type: COMPARATOR
Intervention: Chinolones
Number of subjects: 300
Study: 11727285

Group type: EXPERIMENTAL
Intervention: Platelets prepared with Helinx technology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard platelet transfusions (implied control)
Number of subjects: 0
Study: 9594322

Group type: EXPERIMENTAL
Intervention: r‐SK
Number of subjects: 173

Group type: COMPARATOR
Intervention: SK
Number of subjects: 173
Study: 7936246

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients (side of stenosis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients (normal side)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients (one month after carotid endarterectomy, side of stenosis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients (one month after carotid endarterectomy, normal side)
Number of subjects: 0
Study: 2595039

Group type: EXPERIMENTAL
Intervention: Alfentanil (median dose 1.1 mg, range 0.5-2.6 mg)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Papaveretum (median dose 10 mg, range 5-15 mg) and Diazepam (median dose 8 mg, range 0-20 mg)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 76
Study: 1106038

Group type: EXPERIMENTAL
Intervention: Safapryn (3.6 g aspirin + 3.0 g paracetamol daily)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Phenylbutazone (3000 mg)
Number of subjects: 122

Group type: COMPARATOR
Intervention: 50 mg phenylbutazone daily
Number of subjects: 122
Study: 31625704

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 132

Group type: COMPARATOR
Intervention: Conventional therapy (ACE inhibitors or ARBs)
Number of subjects: 132
Study: 28760590

Group type: EXPERIMENTAL
Intervention: Clotrimazole vaginal ointment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Honey vaginal ointment
Number of subjects: 80
Study: 25674350

Group type: EXPERIMENTAL
Intervention: Integrated Management of Neonatal and Childhood Illness (IMNCI) strategy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18
Study: 23260167

Group type: EXPERIMENTAL
Intervention: Active management consultations
Number of subjects: 3851

Group type: EXPERIMENTAL
Intervention: Physiotherapy package (up to six sessions)
Number of subjects: 3851

Group type: COMPARATOR
Intervention: Usual care consultations
Number of subjects: 3851

Group type: COMPARATOR
Intervention: Single physiotherapy advice session
Number of subjects: 3851
Study: 21663857

Group type: EXPERIMENTAL
Intervention: Docetaxel 38 mg/m²
Number of subjects: 130

Group type: COMPARATOR
Intervention: Vinorelbine 25 mg/m²
Number of subjects: 130
Study: 19636254

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 22067557

Group type: EXPERIMENTAL
Intervention: Aspheric AcrySof SN60WF IOL
Number of subjects: 47

Group type: COMPARATOR
Intervention: Spherical AcrySof SN60AT IOL
Number of subjects: 47
Study: 15830733

Group type: EXPERIMENTAL
Intervention: Intranasal cocaine (1 mg/kg every 30 min) with oral alcohol (1 g/kg following the initial cocaine dose and a second drink at +60 min)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Cocaine and alcohol placebo
Number of subjects: 17

Group type: COMPARATOR
Intervention: Cocaine placebo and alcohol
Number of subjects: 17
Study: 12855610

Group type: EXPERIMENTAL
Intervention: 4 mg of zoledronic acid (Zol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 8 mg of zoledronic acid (Zol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: zoledronic acid (Zol)
Number of subjects: 0
Study: 9856709

Group type: COMPARATOR
Intervention: Fentanyl (3 microg/ml) alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fentanyl with 0.01% bupivacaine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fentanyl with 0.5 microg/ml epinephrine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fentanyl with both 0.01% bupivacaine and 0.5 microg/ml epinephrine
Number of subjects: 100
Study: 7824105

Group type: EXPERIMENTAL
Intervention: CAG repeat length analysis
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Paternal transmission of CAG repeats
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Maternal transmission of CAG repeats
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Father-child differences in repeat length
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: CAG repeat length analysis as a diagnostic test
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Expansion of CAG repeats
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Effect of transmitting parent's sex
Number of subjects: 71
Study: 2215707

Group type: EXPERIMENTAL
Intervention: Electronic blood pressure meter
Number of subjects: 76

Group type: COMPARATOR
Intervention: Mercury manometer
Number of subjects: 76
Study: 382154

Group type: EXPERIMENTAL
Intervention: 1% domperidone drops (0.3 mg/kg t.d.s. before meals)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 1% metoclopramide drops (0.3 mg/kg t.d.s. before meals)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 11383934

Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (tPA) treatment with imaging exclusion criteria
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (tPA) treatment
Number of subjects: 30
Study: 31508533

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (Mg) during even-numbered chemotherapy courses (arm AB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No magnesium supplementation during odd-numbered chemotherapy courses (arm BA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (Mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No magnesium supplementation
Number of subjects: 40
Study: 29370555

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 130
Study: 27443660

Group type: EXPERIMENTAL
Intervention: Pharmathen quetiapine 400 mg prolonged-release formulation
Number of subjects: 48

Group type: COMPARATOR
Intervention: AstraZeneca Seroquel Prolong® 400 mg prolonged-release formulation
Number of subjects: 48
Study: 25374047

Group type: EXPERIMENTAL
Intervention: One-sided message describing the advantages of HIV testing
Number of subjects: 1919

Group type: EXPERIMENTAL
Intervention: Two-sided message acknowledging a superficial objection (20 minute wait for results)
Number of subjects: 1919

Group type: EXPERIMENTAL
Intervention: Two-sided message acknowledging a serious objection (fear of testing positive for HIV)
Number of subjects: 1919

Group type: COMPARATOR
Intervention: Information-only control
Number of subjects: 1919
Study: 22173140

Group type: EXPERIMENTAL
Intervention: Mass distribution of a single dose of oral azithromycin for trachoma
Number of subjects: 1036

Group type: COMPARATOR
Intervention: Nontreated communities (control)
Number of subjects: 1036
Study: 21526662

Group type: EXPERIMENTAL
Intervention: Target-controlled infusion (TCI) with propofol 4 microg/ml and remifentanil 4 ng/ml
Number of subjects: 60

Group type: COMPARATOR
Intervention: Manually controlled infusion (MCI) with conventional-dose-weight infusion method
Number of subjects: 60

Group type: COMPARATOR
Intervention: Manually controlled infusion (MCI)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Target-controlled infusion (TCI)
Number of subjects: 60
Study: 17671052

Group type: EXPERIMENTAL
Intervention: Bedside case presentation
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conference-room case presentation
Number of subjects: 27
Study: 15836571

Group type: EXPERIMENTAL
Intervention: 3-mg subcutaneous sumatriptan
Number of subjects: 30

Group type: COMPARATOR
Intervention: 6-mg subcutaneous sumatriptan
Number of subjects: 30
Study: 11950434

Group type: EXPERIMENTAL
Intervention: Maharishi Vedic Medicine (MVM)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Modern medicine (conventional dietary, exercise, and multivitamin approaches)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Usual care (no added intervention)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Maharishi Vedic Medicine (MVM) for high-risk subjects
Number of subjects: 57

Group type: COMPARATOR
Intervention: Usual care for high-risk subjects
Number of subjects: 57

Group type: COMPARATOR
Intervention: Modern medicine for high-risk subjects
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Maharishi Vedic Medicine (MVM) overall
Number of subjects: 57
Study: 9452325

Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 335

Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 335
Study: 8590577

Group type: EXPERIMENTAL
Intervention: Albendazole sulphoxide (ABZS) administered orally
Number of subjects: 0

Group type: COMPARATOR
Intervention: Albendazole (ABZ) administered orally
Number of subjects: 0
Study: 2273117

Group type: EXPERIMENTAL
Intervention: Immediate closure (group A, n = 10 patients)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Prolonged procedures such as Mohs micrographic surgery (group B, n = 15 patients)
Number of subjects: 25
Study: 81655

Group type: EXPERIMENTAL
Intervention: Inosiplex (drug-treated patients)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 13
Study: 31928489

Group type: EXPERIMENTAL
Intervention: Fitbit device and buddy system
Number of subjects: 13

Group type: COMPARATOR
Intervention: Automated text messages
Number of subjects: 13
Study: 31050628

Group type: EXPERIMENTAL
Intervention: Iclaprim with MIC > 8 µg/ml
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Iclaprim
Number of subjects: 790
Study: 27221810

Group type: EXPERIMENTAL
Intervention: Mechanical occlusion chemically assisted endovenous ablation (MOCA)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Radiofrequency endovenous ablation (RFA)
Number of subjects: 170
Study: 25413621

Group type: EXPERIMENTAL
Intervention: tDCS (0.7 mA for 10 minutes applied to bilateral primary motor cortices)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 13
Study: 23458162

Group type: EXPERIMENTAL
Intervention: Veriset™ haemostatic patch
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fibrin sealant patch (TachoSil(®))
Number of subjects: 50
Study: 21191313

Group type: EXPERIMENTAL
Intervention: Tailored individual doses of radioiodine (¹³¹I) and low-dose antithyroid drug (ATD)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group with fixed dose of radioiodine set as 2.96 MBq/g of thyroid
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Low-dose ATD used in study group
Number of subjects: 118
Study: 19904665

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Relapse Prevention (MBRP)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 168
Study: 16571905

Group type: EXPERIMENTAL
Intervention: Nondominant hand movements during intentional switches between in-phase and antiphase coordination patterns.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right-handed participants performing voluntary switches.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Left-handed participants performing voluntary switches.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Switches from in-phase to antiphase coordination.
Number of subjects: 0
Study: 12682825

Group type: EXPERIMENTAL
Intervention: benfluorex (150-450 mg/day)
Number of subjects: 722

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: benfluorex
Number of subjects: 722

Group type: COMPARATOR
Intervention: metformin
Number of subjects: 722
Study: 10548199

Group type: EXPERIMENTAL
Intervention: Hypertonic saline 7.2%-hydroxyethyl starch 6% solution (HS-HES group)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Hypertonic saline 7.2% solution (HS group)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Hydroxyethyl starch 6% solution (HES group)
Number of subjects: 26
Study: 8913317

Group type: EXPERIMENTAL
Intervention: Chlorambucil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etoposide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorambucil (before and after treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal control subjects' lymphocytes
Number of subjects: 0
Study: 1760997

Group type: EXPERIMENTAL
Intervention: Oleic acid diet
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Trans fatty acid diet
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Saturated fatty acid diet
Number of subjects: 59
Study: 7199345

Group type: EXPERIMENTAL
Intervention: Remid preparation of allopurinol, 300 mg p.o. dose
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard preparation of allopurinol, 300 mg p.o. dose
Number of subjects: 10
Study: 31873950

Group type: EXPERIMENTAL
Intervention: SND without level 2b dissection (group 1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: SND with level 2b dissection (group 2)
Number of subjects: 30
Study: 31712574

Group type: EXPERIMENTAL
Intervention: Excitatory tDCS during initial training
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham (placebo) tDCS
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Excitatory tDCS during incubation period
Number of subjects: 100
Study: 28832406

Group type: EXPERIMENTAL
Intervention: Vitamin D3 and calcium supplementation
Number of subjects: 165

Group type: COMPARATOR
Intervention: Baseline total 25‐(OH)D
Number of subjects: 165

Group type: COMPARATOR
Intervention: Baseline bioavailable 25‐(OH)D
Number of subjects: 165
Study: 26498331

Group type: EXPERIMENTAL
Intervention: SMS reminders sent to parents before EPI sessions
Number of subjects: 523

Group type: COMPARATOR
Intervention: Ordinary methods of informing parents
Number of subjects: 523
Study: 23465966

Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Schizophrenia and bipolar patients
Number of subjects: 69
Study: 21621629

Group type: EXPERIMENTAL
Intervention: Extracorporeal photopheresis (ECP) administered 3 times during week 1, then twice weekly until week 12, followed by 2 treatments monthly until week 24.
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard of care non-ECP (control) arm
Number of subjects: 29
Study: 18945998

Group type: EXPERIMENTAL
Intervention: Lateral DXA measurement of aortic VC
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CT measurement of aortic VC
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lateral DXA VC > or = 6 on a 24-point scale
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lateral DXA-reported BMD
Number of subjects: 40

Group type: COMPARATOR
Intervention: AP DXA-reported BMD
Number of subjects: 40
Study: 16568198

Group type: EXPERIMENTAL
Intervention: Tropisetron (5 mg)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Tropisetron-Propofol (5 mg tropisetron and 0.5 mg/kg propofol)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 105
Study: 12937042

Group type: EXPERIMENTAL
Intervention: DHA supplementation (fish oil capsules rich in DHA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo supplementation (placebo capsules)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DHA status of infants at birth
Number of subjects: 100
Study: 11079527

Group type: EXPERIMENTAL
Intervention: High-load resistance training (80%, 1-RM, 8 reps)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High-repetition resistance training (40%, 1-RM, 16 reps)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study: 9762660

Group type: EXPERIMENTAL
Intervention: Intrathecal immunoglobulin synthesis (IgA, IgG, IgM) and complement activation in MS patients
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intrathecal immunoglobulin synthesis (IgG, IgA, IgM)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Full activation of the complement cascade
Number of subjects: 48
Study: 7918843

Group type: EXPERIMENTAL
Intervention: Tibolone (Livial)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oestradiol valerate combined with cyproterone acetate (Climen)
Number of subjects: 30
Study: 3414321

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Propanthelene
Number of subjects: 13
Study: 29686009

Group type: EXPERIMENTAL
Intervention: Tight control (target diastolic blood pressure, 85 mm Hg)
Number of subjects: 981

Group type: COMPARATOR
Intervention: Less-tight control (target diastolic blood pressure, 100 mm Hg)
Number of subjects: 981
Study: 28490514

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 IU cholecalciferol bolus followed by 4000 IU cholecalciferol/d)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 65
Study: 26109261

Group type: EXPERIMENTAL
Intervention: Self-questionnaire completed on a dedicated website
Number of subjects: 1141

Group type: COMPARATOR
Intervention: Telephone interview
Number of subjects: 1141
Study: 24685788

Group type: EXPERIMENTAL
Intervention: BisBlock dentin desensitizer (Bisco Inc.)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GC Tooth Mousse desensitizer (GC Asia)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Systemp desensitizer (Ivoclar Vivadent)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no desensitizer application)
Number of subjects: 30
Study: 21122499

Group type: EXPERIMENTAL
Intervention: Budesonide-MMX® 9 mg tablets
Number of subjects: 36
Study: 18261024

Group type: EXPERIMENTAL
Intervention: Melatonin treatment
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 17052562

Group type: EXPERIMENTAL
Intervention: 40‐minute nap opportunity at 3 AM
Number of subjects: 49
Study: 12386359

Group type: EXPERIMENTAL
Intervention: One-layer closure of the vaginal cuff
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Two-layer closure of the vaginal cuff
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Open vaginal cuff
Number of subjects: 427